Recombinant
RabMAb

Recombinant Anti-Osteoprotegerin antibody [EPR17649-152] (ab222585)

Overview

  • Product name

    Anti-Osteoprotegerin antibody [EPR17649-152]
    See all Osteoprotegerin primary antibodies
  • Description

    Rabbit monoclonal [EPR17649-152] to Osteoprotegerin
  • Host species

    Rabbit
  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Species reactivity

    Reacts with: Mouse
  • Immunogen

    The details of the immunogen for this antibody are not available.

  • General notes

    Anti-Osteoprotegerin antibody (ab222585) is used in our 90-minute ELISA kit, Mouse Osteoprotegerin ELISA kit (ab203365), and available in the matched antibody pair kit (ab215078).

Properties

Applications

Our Abpromise guarantee covers the use of ab222585 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Target

  • Function

    Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • Tissue specificity

    Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • Involvement in disease

    Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • Sequence similarities

    Contains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • Post-translational
    modifications

    N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • Cellular localization

    Secreted.
  • Information by UniProt
  • Database links

  • Alternative names

    • MGC29565 antibody
    • OCIF antibody
    • OPG antibody
    • Osteoclastogenesis inhibitory factor antibody
    • Osteoprotegerin antibody
    • PDB5 antibody
    • TNF receptor superfamily member 11b antibody
    • TNFRSF 11B antibody
    • TNFRSF11B antibody
    • TR 1 antibody
    • TR1 antibody
    • TR11B_HUMAN antibody
    • Tumor necrosis factor receptor superfamily member 11B antibody
    see all

Images

  • Example of mouse Osteoprotegerin standard curve in 1X Cell Extraction Buffer PTR using recombinant Osteoprotegerin RabMAb antibody (ab222585) and a recombinant monoclonal antibody. Background-subtracted values (mean +/- SD) are graphed.

    For a matched antibody pair set, see Mouse Osteoprotegerin Matched Antibody Pair Kit (ab215078).

    For a complete ELISA kit, see Mouse Osteoprotegerin ELISA kit (ab203365).

References

ab222585 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab222585.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up